NewEdge Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $1.08M | Buy |
19,664
+15,895
| +422% | +$874K | 0.01% | 1238 |
|
2025
Q1 | $266K | Buy |
3,769
+388
| +11% | +$27.4K | ﹤0.01% | 1963 |
|
2024
Q4 | $222K | Buy |
3,381
+3,121
| +1,200% | +$205K | ﹤0.01% | 2038 |
|
2024
Q3 | $18.3K | Sell |
260
-10,625
| -98% | -$747K | ﹤0.01% | 2743 |
|
2024
Q2 | $896K | Buy |
10,885
+10,615
| +3,931% | +$874K | 0.01% | 1125 |
|
2024
Q1 | $23.6K | Sell |
270
-36
| -12% | -$3.14K | ﹤0.01% | 2578 |
|
2023
Q4 | $29.5K | Buy |
306
+134
| +78% | +$12.9K | ﹤0.01% | 2419 |
|
2023
Q3 | $15.2K | Sell |
172
-14
| -8% | -$1.24K | ﹤0.01% | 2450 |
|
2023
Q2 | $16.1K | Sell |
186
-452
| -71% | -$39.2K | ﹤0.01% | 2443 |
|
2023
Q1 | $62K | Sell |
638
-326
| -34% | -$31.7K | ﹤0.01% | 1909 |
|
2022
Q4 | $78.2K | Buy |
+964
| New | +$78.2K | ﹤0.01% | 1538 |
|
2021
Q4 | – | Sell |
-6,333
| Closed | -$489K | – | 1640 |
|
2021
Q3 | $489K | Sell |
6,333
-23
| -0.4% | -$1.78K | 0.01% | 755 |
|
2021
Q2 | $530K | Buy |
6,356
+139
| +2% | +$11.6K | 0.01% | 724 |
|
2021
Q1 | $469K | Buy |
6,217
+100
| +2% | +$7.54K | 0.01% | 673 |
|
2020
Q4 | $536K | Buy |
6,117
+2,566
| +72% | +$225K | 0.02% | 603 |
|
2020
Q3 | $270K | Buy |
3,551
+1,108
| +45% | +$84.2K | 0.01% | 747 |
|
2020
Q2 | $301K | Buy |
+2,443
| New | +$301K | 0.01% | 671 |
|